Biotechnology entrepreneurship and ethics: Principles, paradigms, and products

Medicine and Law

Volumn 25, Issue 3, 2006, Pages 491-502

  Kuszler, Patricia C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biotechnology; Ethics; Global health

Indexed keywords

DNA; DRUG;

ABUSE; BIOTECHNOLOGY; COMMERCIAL PHENOMENA; CONFLICT OF INTEREST; DNA DETERMINATION; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; GENE TECHNOLOGY; GENETICALLY MODIFIED FOOD; GOVERNMENT; HAZARD ASSESSMENT; HUMAN; MEDICAL EDUCATION; MEDICAL ETHICS; PATIENT SAFETY; RESEARCH ETHICS; RESEARCH SUBJECT; REVIEW; RISK BENEFIT ANALYSIS; UNITED STATES;

EID: 33750174401     PISSN: 07231393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Marcia Angell, Is Academic Medical for Sale? 341 New Eng. J Med. 1516, 1517 (2000)
2. Tom L. Beauchamp & James F. Childress, Principles of Biomedical Ethics 340-345; 348-353 (5th ed. 2001).
3. The Belmont Report: Ethical Guidelines for the Protection of Human Subjects of Research, available at http://www.hhs.gov/ohrp/ binnansubjects/guidance/belmont.htm
4. Elizabeth A. Boyd & Lisa A. Bero, Assessing Faculty Financial Relationships With Industry: A Case Study, 284 JAMA 2209 (2000)
5. Edward B. Flowers, Ethics and Economics of Patenting the Human Genome, 17 J. Business Ethics 1737 (1999)
6. ICMJE, Conflict of Interest: Writing for Publication, 341 Lancet 742 (1993)
7. Sheldon Krimsky et al., Financial Interest and its Disclosure in Scientific Publications, 280 JAMA 225 (1998)
8. Patricia C. Kuszler, Curing Conflicts of Interest in Clinical Research: Impossible Dreams and Harsh Realities, 8 Widener Law Symposium Journal 115 (2001).
9. Bernard Lo, et al., Conflict-of-Interest Policies for Investigators in Clinical Trials, 343 New Eng. J. Med. 1616 (2000)
10. Peter J. Neumann & Eileen A Sandberg, Trends in Health Care R & D And Technology Innovation, Health Aff., Nov.-Dec. 1998, at 111